Related Experiment Video

Updated: May 13, 2026

High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment
07:26

High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment

Published on: July 18, 2017

Genetic variation in C-reactive protein in ethnic Chinese population in Taiwan

Chin-Chou Huang1, Chia-Min Chung, Hsin-Bang Leu

  • 1Department of Medical Research and Education, Taipei Veterans General Hospital, Taipei, Taiwan.

European Journal of Clinical Investigation
|March 19, 2013
PubMed

Insights

Genetic factors have a limited impact on high-sensitivity C-reactive protein (hs-CRP) levels in well-controlled hypertensive patients. Clinical factors, such as BMI and age, are more significant determinants of hs-CRP for cardiovascular risk stratification.

Area of Science:

  • Cardiovascular Genetics
  • Inflammation Biomarkers
  • Hypertension Research

Background:

  • High-sensitivity C-reactive protein (hs-CRP) is a key inflammatory marker for cardiovascular risk assessment.
  • Understanding genetic influences on hs-CRP is crucial for refining risk stratification in hypertensive populations.

Purpose of the Study:

  • To investigate the genetic determinants of serum hs-CRP levels in a cohort of nondiabetic hypertensive patients.
  • To assess the relative contributions of genetic and clinical factors to hs-CRP variability.

Main Methods:

  • Genotyping of four single-nucleotide polymorphisms (SNPs) in the CRP gene (rs1572970, rs2794520, rs3093077, rs2808630) was performed in two stages.
  • Serum hs-CRP levels were measured and analyzed in relation to clinical parameters and identified SNPs in 915 ethnic Chinese hypertensive patients.

Main Results:

  • Two SNPs, rs1572970 and rs3093077, showed correlation with hs-CRP levels.
  • Age, body mass index (BMI), waist-hip ratio, smoking, night-time systolic blood pressure, and total cholesterol were independently associated with hs-CRP.
  • Genetic factors explained only 2.4% of the interindividual variability in hs-CRP levels, whereas BMI explained 11.9%.

Conclusions:

  • C-reactive protein genotype has a limited contribution to serum hs-CRP levels in well-controlled hypertensive individuals.
  • Clinical determinants play a more significant role than genetic factors in influencing hs-CRP levels for cardiovascular risk stratification in this Taiwanese cohort.
Abstract

More Related Videos

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry05:53

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry

Published on: June 21, 2018

Related Concept Videos

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Single Nucleotide Polymorphisms-SNPs01:05

Single Nucleotide Polymorphisms-SNPs

A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
Comparing Copy Number Variations and SNPs02:26

Comparing Copy Number Variations and SNPs

Sequencing of the human genome has opened up several best-kept secrets of the genome. Scientists have identified thousands of genome variations that exist within a population. These variations can be a single nucleotide or a larger chromosomal variation.
Copy number variations or CNVs are the structural variations that cover more than 1kb of DNA sequence. The single nucleotide polymorphism (SNP), on the other hand, is a single nucleotide change or a point mutation that is found in more than 1%...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...